Polymorphism distribution of rs316019 of SLC22A2 in the Uygur population of Xinjiang

Abstract

Abstract:

AIM: To study the polymorphism distribution of SLC22A2 gene rs316019 loci in Uygur of Xinjiang, and to analyze the racial differences in different populations. METHODS: The genotypes of rs316019 loci(G808T,A270S)in 276 unrelated healthy Uygur male were detected by the techniques of SNaP shot, and the genotype and allele frequency were subsequently compared with different populations, and analyzed the racial differences in their distribution. RESULTS:The genotypes distribution of rs316019 loci was in the Hardy-Weinberg equilibrium (P>0.05). The frequencies of genotypes (CC, CA, and AA) were 79.7%,18.1% and 2.2% in Xinjiang Uygur, the frequency of minor allele A was 11.2%, the allele G or T were not observed. It's polymorphism distribution showed significant differences between Xinjiang Uygur and the Han, the African, the American and European populations etc. (P＜0.05). CONCLUSION: There was national difference in polymorphism of SLC22A2 rs316019 loci among different populations, and it may bring the difference to drugs' pharmacogenetics and related diseases' development etc. accordingly.

Key words: SLC22A2 gene, rs316019 loci, genetic polymorphism, Uygur

CLC Number:

R968

ZHOU Yuan, LU Xueling, ZHAO Jun, ZHANG Li, YANG Huanjie，WANG Ning. Polymorphism distribution of rs316019 of SLC22A2 in the Uygur population of Xinjiang[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 287-293.

References

［1］International Diabetes Federation. Title of subordinate document. In: Diabetes Atlas 6th ed［EB/OL］. ［2014-2-15］.http://www.idf.org/sites/default/files/Atlas-poster-2014_EN.pdf.
［2］陈培贤.SLC22A1，SLC22A2，SLC47A1，SLC47A2，ATM基因多态性对二甲双胍药物疗效及不良反应的影响［D］.汕头大学,2014.
［3］陈丹丹.人类有机阳离子转运体2(OCT2)808G＞T对健康受试者体内盐酸二甲双胍药代动力学和药效学的影响［D］.中南大学,2008.
［4］Zhang J, Zhou W. Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients［J］. Food Chem Toxicol, 2012,50(7): 2289-2293.
［5］Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin［J］. Clin Pharmacol Ther, 2009,86(3): 299-306.
［6］Christensen MM, Brasch-Andersen C, Green H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c［J］. Pharmacogenet Genomics, 2011, 21（12）: 837-850.
［7］Leabman MK, Huang CC, Kawamoto M, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function［J］. Pharmacogenetics, 2002, 12(5): 395-405.
［8］Fukushima-Uesaka H, Maekawa K, Ozawa S, et al. Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2) ［J］. Drug Metab Pharmacokinet, 2004,19(3): 239-244.
［9］Kang HJ, Song IS, Shin HJ, et al. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population［J］. Drug Metab Dispos, 2007,35（4）: 667-675.
［10］Yoon H, Cho HY, Yoo HD, et al. Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects［J］. AAPS J, 2013,15（2）: 571-580.
［11］Zhang L, Dresser MJ, Gray AT, et al. Cloning and functional expression of a human liver organic cation transporter［J］. Mol Pharmacol, 1997,51（6）: 913-921.
［12］Burger H，Van TH，Boersma Aw,et al.Imatinib mesylate(ST1571)is a substrate for the breast cancer resistance protein(BCRP)／ABcG2 drag pump ［J］．Blood，2004，104 (9)：2940-2942．
［13］Kimura N, Masuda S, Tanihara Y, et al. Metfomain is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1［J］. Drug Metab Phammcokinet , 2005, 20（5）: 379-386.
［14］Song IS, Shin HJ, Shim EJ, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin［J］. Clin Pharmacol Ther, 2008, 84（5）: 559-562.
［15］Chen Y, Li S, Brown C, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin［J］. Pharmacogenet Genomics, 2009,19（7）: 497-504.
［16］Wang ZJ, Yin OQ, Tomlinson B, et al.Oct2 polymorphisms and in-vivo renal functional consequence:studies with mefformin and eimetidinc［J］．Pharmacogenet Genomics, 2008, 18(7)：637-645.
［17］Shikata E,Yamamoto R,Takane H,et al.Human organic cation transporter(OCT1) and (OCT2) gene polymorphisms and therapeutic effects of metformin［J］. J Hum Genet, 2007, 52(2):117-122.
［18］Wang ZJ. Genetic polymorphism of human organic cation transporter subtype 2 and genotype-phenotype relationship in Chinese population［D］. The Chinese University of Hong Kong, 2007.
［19］Song IS, Shin HJ, Shim EJ, et al. Genetic variants of SLC22A2 significantly influence metformin disposition［J］. Clin Pharmacol Ther, 2008, 84(5): 559-562.
［20］Lazar A, Zimmermann T, Koch W, et al. Lower prevalence of the OCT2 Ser270 allele in patients with essential hypertension［J］. Clin Exp Hypertens, 2006, 28（7）: 645-653.
［21］Filipski KK, Mathijssen RH, Mikkelsen TS, et al. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity［J］. Clin Pharmacol Ther ,2009, 86（4）: 396-402.
［22］刘芳，李青，郑泰山，等.Identification of the SLC22A2 Genetic Variants (808G/T) by allele specific primer-polymerase chain reaction method and the relevance of its polymorphisms with plasma lactate concentration in Type 2 Diabetics［C］. 南京：中华医学会第八次全国内分泌学学术会议，2009.

[1]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[2]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
[3]	LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa. Relevance of CYP2R1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059.
[4]	CHEN Binyao, LI Ling, ZHAO Huijia, LIU Xiaohong, QI Zhenhua, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, DONG Li, YUE Jiang, YE Qifa. Relevance of CYP1B1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1309-1316.
[5]	LIN Xiuxian, CHEN Dan, ZHAO Qing, CHEN Yao. Genetic research on the incidence of alcoholic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1309-1314.
[6]	HU Jing, ZHU Jun-rong, YU Feng. Efficacy and safety of warfarin dosage algorithms in clinical application:A Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 296-303.
[7]	MA Xiao-qin, XIN Hua-wen, LI Yuan-qi, HUANG Hui, ZHAO Li, YU Ai-rong, LI Wei-liang, WU Xiao-chun. Association of HGPRT activity and gene polymorphism with adverse reactions caused by azathioprine in kidney transplant recipients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 182-187.
[8]	WU Ji-chu, OUYANG Ze-wei, LUO Can-xiang. Effect of ABCG2 genetic polymorphism on atorvastatin modifying serum lipids [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 882-884.
[9]	OUYANG Cang-hong, XIE Juan. Study on the relationship between the MDR1 and CYP3A genetic polymorphisms and serum digoxin concentration in 111 patients with chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 291-296.
[10]	FENG Jing, WU Yue, RONG Pei-pei, SHEN Bing-zheng, ZHOU Ding-shan, SHI Cai, SONG Jin-chun. Progress on effects of pharmacogenetics of inosine triphosphate pyrophosphatase on improving the individualized thiopurine therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1435-1440.
[11]	HUANG Lu, YANG Guo-ping. Progress on influence of cytochrome P450 oxidoreductase polymorphisms on cytochrome P450 monoxyfenases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 818-823.
[12]	NING Wei, LIU Jie. Research advances in pharmacogenomics of levodopa [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 455-460.
[13]	HUANG Qiong, ZHANG Liu-fu, CHENG Yan, SI Li, WEI Wei. Effect of β3-adrenergic receptor gene Trp64Arg polymorphism on uric acid levels in a Chinese male type 2 diabetes mellitus population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 307-311.
[14]	CHEN Bing, CAI Wei-min, YANG Wan-hua. Genetic polymorphism of CYP2D6 and its influence on the personalized usage of antipsychotics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1067-1074.
[15]	HU Lei, GAO Li-chen, ZHUO Wei, ZHOU Hong-hao, FAN Lan. Advances in pharmacogenomics of cytochrome P450 oxidoreductase [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 821-827.